Led AirNexis Therapeutics' $200M Series A launch to advance a Phase 2 dual PDE3/4 inhibitor for COPD.
AirNexis Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies that address unmet medical needs in oncology and autoimmune disorders
AirNexis Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies that address unmet medical needs in oncology and autoimmune disorders.